Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols

Abstract

Background: Quality of life (QoL) is an essential factor in therapeutic decision-making for human patients and is commonly used as an endpoint in clinical trials of cancer treatments.
Aim: To compare owners’ perception of QoL in canine and feline patients affected by different tumor histotypes treated with single-agent or multidrug protocols.
Methods: Owners were asked to assess the impact on QoL of their pets undergoing chemotherapy treatment by answering a questionnaire and assigning a score to different health-related parameters reported to affect QoL.
Results: Questionnaires of 101 patients (85 dogs and 16 cats), collected at different time points, were analyzed. Fiftyseven patients were given single-agent chemotherapy (carboplatin, doxorubicin, lomustine, melphalan, mitoxantrone, vinblastine, and vinorelbine), whereas 44 were given multiple-agent treatment. When diverse factors including chemotherapy treatment type (single-agent vs. multidrug regimens) and the onset and kind of adverse effects were considered, no significant variations in owners’ perceptions of their pets’ QoL were discovered.
Conclusion: Chemotherapy type (single-agent vs. multidrug protocol) and related adverse events are shown, which did not influence owners’ perception of their pet’s QoL. Future prospective studies should look into clinical characteristics that might affect QoL, such as the patient’s age, tumor stage, and protocol purpose (curative vs. palliative).